Amgen IL-1ra Sepsis Data May Help Support Arthritis Launch, Firm Says

Amgen's extensive database for interleukin-1 receptor antagonist in sepsis patients may help the company position the product as a safer alternative to the TNF inhibitor Enbrel in the rheumatoid arthritis market, Amgen Senior VP-Sales & Marketing Stan Benson suggested during a Nov. 8 analysts meeting in New York City.